Our CBID Center will strengthen infrastructure and enable scientists and biomedical research in the State of Kansas. The center capitalizes on existing strengths and resources, including some that have resulted from previous COBRE efforts in cancer chemotherapy, high-throughput screening, medicinal chemistry, and proteomics, while addressing critical gaps that have so far limited the ability of researchers at the University of Kansas (KU) and associated institutions to apply these tools to the study of infectious disease targets.
The CBID is led by Principal Investigator, Thomas Prisinzano, Professor of Medicinal Chemistry. Dr. Prisinzano is a highly experienced medicinal chemist and effective scientific administrator. He will be joined by Scott Hefty, Associate Professor of Molecular Biosciences, as co-I of the overall center. Professor Hefty has over 20 years of experience in infectious diseases and microbial pathogenesis research. In addition to the scientific expertise, both investigators have extensive experience with COBRE administration and associated core facilities at KU.